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Summary
Bortezomib therapy has proven successful for the treatment of relapsed and/or refractory multiple myeloma (MM); how-
ever, prolonged treatment is associated with toxicity and development of drug resistance. Here, we show that the novel
proteasome inhibitor NPI-0052 induces apoptosis in MM cells resistant to conventional and Bortezomib therapies. NPI-
0052 is distinct from Bortezomib in its chemical structure, effects on proteasome activities, mechanisms of action, and
toxicity profile against normal cells. Moreover, NPI-0052 is orally bioactive. In animal tumor model studies, NPI-0052 is
well tolerated and prolongs survival, with significantly reduced tumor recurrence. Combining NPI-0052 and Bortezomib
induces synergistic anti-MM activity. Our study therefore provides the rationale for clinical protocols evaluating NPI-0052,
alone and together with Bortezomib, to improve patient outcome in MM.S I G N I F I C A N C E
The ubiquitin-proteasome pathway modulates intracellular protein degradation. The multienzyme protease 26S proteasome de-
grades misfolded proteins; conversely, blockade of the proteasomal degradation pathways results in accumulation of unwanted
proteins and cell death. Because cancer cells proliferate to a greater extent than normal cells, the rate of protein translation and
degradation is also higher. This notion led to the development of proteasome inhibitors as cancer therapeutics. Recently, the FDA
approved the first proteasome inhibitor, Bortezomib (Velcade), for treatment of relapsed/refractory multiple myeloma (MM). This
study shows that the orally bioavailable novel proteasome inhibitor NPI-0052 is cytotoxic to MM cells, with reduced toxicity against
normal cells compared to Bortezomib, providing the framework for clinical trials of NPI-0052 in MM.Introduction
The successful development of Bortezomib/PS-341 Velcade
therapy for treatment of relapsed/refractory multiple myeloma
(MM) has established proteasome inhibition as an effective
therapeutic strategy. The dipeptide boronic acid analog Borte-
zomib is a potent, highly selective, and reversible proteasome
inhibitor that targets the 26S proteasome complex and inhibits
its function (Adams et al., 1999). Besides inhibiting NF-κB, Bor-
tezomib has pleiotropic effects on MM biology by targeting (1)
cell cycle regulatory proteins; (2) the unfolded protein response
(UPR) pathway; (3) p53-mediated apoptosis; and (4) DNA re-
pair mechanisms; as well as (5) classical stress response path-
ways via both intrinsic (caspase-9-mediated) and extrinsic
(caspase-8-mediated) cell death cascades. Specifically, Bor-
tezomib activates c-Jun amino-terminal kinase (JNK) (Chauhan
et al., 2003), which triggers mitochondrial apoptotic signaling:CANCER CELL : NOVEMBER 2005 · VOL. 8 · COPYRIGHT © 2005 ELSEVIErelease of cytochrome-c (cyto-c) and second mitochondrial ac-
tivator of caspases (Smac) from mitochondria to cytosol, fol-
lowed by activation of caspase-9 and caspase-3 (Chauhan and
Anderson, 2003). Despite the potent anti-MM activity of Bor-
tezomib, both intrinsic and acquired resistance has already
been observed in MM patients (Anderson, 2004). The mecha-
nisms conferring Bortezomib resistance are now being defined
(Chauhan et al., 2005). Nonetheless, the combination of Bor-
tezomib with other novel and conventional agents can over-
come Bortezomib resistance (Chauhan et al., 2005).
Recent studies have focused on developing other protea-
some inhibitors as therapeutics in cancer. NPI-0052 is one
such molecule derived from fermentation of Salinospora, a new
marine gram-positive actinomycete (Macherla et al., 2005). In
the present study, we show that both NPI-0052 and Bortezo-
mib can be distinguished by chemical structure, their effects
on proteasomal activities, and differential toxicity profilesR INC. DOI 10.1016/j.ccr.2005.10.013 407
A R T I C L Eagainst normal cells. NPI-0052 induces apoptosis in MM cell
lines and patient cells. Both biochemical and genetic studies
show that NPI-0052-induced cell death, in contrast to that trig-
gered by Bortezomib, relies primarily on caspase-8-mediated
signaling pathways. In vivo studies show that NPI-0052 signifi-
cantly inhibits tumor growth in mice, is well tolerated, and pro-
longs survival. Based on their structural and mechanistic differ-
ences, NPI-0052 and Bortezomib show synergistic anti-MM
activity. Finally, current Bortezomib therapy requires intrave-
nous (i.v.) administration, whereas NPI-0052 is orally bioactive.
Overall, our study provides the rationale for clinical protocols
evaluating NPI-0052 to inhibit tumor cell growth, overcome
conventional and Bortezomib resistance, limit toxicity profiles,
and improve patient outcome in MM.
Results and discussion
NPI-0052 is structurally distinct from Bortezomib
and inhibits all three protease activities within
the proteasome both in vitro and in vivo
The naturally occurring and synthetic inhibitors of the ubiquitin-
proteasome pathway include peptide aldehydes, peptide bo-
ronates, nonpeptide inhibitors, peptide vinyl sulfones, and pep-
tide epoxyketones (Adams, 2004; Adams et al., 1999; Chauhan
et al., 2005). Bortezomib/PS-341/Velcade is a boronic acid di-
peptide derivative and inhibits proteasome function via interac-
tion of boronic acid at the C terminus of Bortezomib with an
active threonine site in the proteasome (Adams et al., 1999)
(Figure 1A). NPI-0052 is a nonpeptide proteasome inhibitor and
shares structural features with another proteasome inhibitor,
Omuralide (Figure 1A), which inhibits proteasome activity by
covalently modifying the active site threonine residues of the
proteasome (Corey and Li, 1999). Omuralide is clasto-lactacys-
tin β-lactone, the active form of the well-known proteasome
inhibitor lactacystin (Corey and Li, 1999). Despite the structural
similarity with Omuralide, NPI-0052 can be distinguished by
the presence of a uniquely methylated C3 ring juncture, chlori-
nated alkyl group at C2, and cyclohexene ring at C5 (Figure
1A). Evaluation of the effects of NPI-0052, Omuralide, and Bor-
tezomib on cathepsin A activity show that Omuralide is a more
specific inhibitor of cathepsin A (IC50 = 65 ± 6 nM). Both NPI-
0052 and Bortezomib also inhibited cathepsin A with different
IC50 (NPI-0052, 1.4 ± 0.1 M; Bortezomib, 14 ± 5 M).
Omuralide is known to inhibit all three protease activities in
the proteasome: the chymotrypsin-like (CT-L), trypsin-like (T-L),
and caspase-like (C-L) activities (Corey and Li, 1999); however,
the effect of NPI-0052 on these proteasome activities is unde-
fined. We therefore examined whether NPI-0052 affects these
proteasome activities using human erythrocyte 20S protea-
somes and fluorogenic peptide substrates. We also simulta-
neously compared the effect of Bortezomib on proteasome
activities. Both NPI-0052 and Bortezomib inhibit all three pro-
teasome activities, albeit at different concentrations (Figures
1B–1D). Results show that (1) NPI-0052 inhibits CT-L and T-L
activities at lower concentrations than Bortezomib, and (2)
higher concentrations of NPI-0052 than Bortezomib are re-
quired to inhibit C-L activity. Our in vitro data suggest that NPI-
0052, like Bortezomib, targets proteasomes.
We next compared the effects of NPI-0052 and Bortezomib
on all three proteasome activities in vivo in mice. For these
studies we selected the MTD dose for each agent. Based on408our previous study (LeBlanc et al., 2002), the MTD of Bortezo-
mib is 1.0 mg/kg (i.v.) given twice weekly. Additional experi-
mentation in beige-nude-xid (BNX) mice established the MTD
of NPI-0052 at 0.15 mg/kg (i.v.) twice weekly (data not shown).
Mice were treated with a single dose of NPI-0052 (0.15 mg/kg
i.v.) or Bortezomib (1 mg/kg i.v.); blood samples were collected
at 90 min, 24 hr, 48 hr, 72 hr, or 168 hr; and whole blood cells
were then analyzed for proteasome activity (Figure 2). NPI-
0052 completely inhibited CT-L activity by 90 min, which was
recoverable by 168 hr (Figure 2A), whereas Bortezomib-inhib-
ited CT-L activity was markedly restored at 24 hr (Figure 2B).
T-L activity is significantly inhibited (50% inhibition) by NPI-
0052 at 90 min, 24 hr, 48 hr, and 72 hr and is restored by 168
hr (Figure 2C); in contrast, Bortezomib enhances T-L activity,
which remains elevated even at 168 hr (Figure 2D). Finally, NPI-
0052 inhibits C-L activity at 90 min, 24 hr, 48 hr, and 72 hr, and
this activity recovered at 168 hr (Figure 2E), whereas Bortezo-
mib significantly inhibits C-L activity at 90 min, 24 hr, 48 hr,
and 72 hr and is similarly recoverable at 168 hr (Figure 2F).
Therefore, after NPI-0052 treatment, all three proteasome
activities remain inhibited at 72 hr and were restored to signifi-
cant levels by 168 hr. These data suggest that NPI-0052 and
Bortezomib differentially affect all three proteasome activities.
NPI-0052 is orally bioactive
Previous studies showed that Bortezomib is orally active (Pa-
lombella et al., 1998; Teicher et al., 1999); however, the current
Bortezomib therapy in MM is administered i.v. The rationale for
using the i.v. route instead of oral administration may include
bioavailability, rapid distribution (Adams et al., 1999), solubility,
and reversibility/half-life issues. We therefore next examined
whether NPI-0052 is also orally bioactive. Mice were treated
with various oral and i.v. concentrations of NPI-0052; at 90 min
whole-blood lysates (WBL) were analyzed for proteasome ac-
tivity. Oral administration of NPI-0052 significantly inhibits
CT-L activity of 20S proteasomes in a dose-dependent manner
between 0.025 mg/kg and 0.50 mg/kg (Figure 3A). Both T-L
and C-L activities were also inhibited, albeit to lesser extent
(data not shown). These findings show that NPI-0052 given
orally inhibits proteasome activity in vivo.
NPI-0052 targets nuclear factor-κB
A major rationale for using Bortezomib therapeutically is its
ability to inhibit nuclear factor-κB (NF-κB) activation (Adams,
2002; Hideshima et al., 2002; Russo et al., 2001). We therefore
next asked whether NPI-0052 similarly affects NF-κB activa-
tion. To address this issue, a stable HEK-293 clone was gener-
ated carrying a luciferase reporter gene under the regulation of
5× NF-κB binding sites. Stimulation of these cells with human
TNF-α leads to increased luciferase activity due to NF-κB acti-
vation. Pretreatment of NF-κB/luc HEK-293 cells with NPI-
0052 results in a significant (p < 0.001) dose-dependent de-
crease of luciferase activity after TNF-α stimulation (Figure 3B),
indicating inhibition of NF-κB. Bortezomib also downregulates
NF-κB activity, but at higher concentrations than NPI-0052
(Figure 3B). These findings indicate that NPI-0052 is a more
potent inhibitor of NF-κB than Bortezomib.
Activation of NF-κB triggers transcription and secretion of
various proinflammatory cytokines, such as TNF-α, interleukin-
1-β (IL-1-β), and interleukin-6 (IL-6), which mediate the growth
and survival of tumor cells (Adams, 2002; Hideshima et al.,CANCER CELL : NOVEMBER 2005
A R T I C L EFigure 1. The proteasome inhibitor NPI-0052 is structurally distinct from Bortezomib/PS-341 and attenuates proteasome activity in vitro
A: Chemical structures of the proteasome inhibitors Bortezomib, NPI-0052, and Omuralide.
B–D: NPI-0052 and Bortezomib inhibit CT-L, C-L, and T-L proteasome activities in human erythrocyte-derived 20S proteasomes. The EC50 values are the drug
concentration at which 50% maximal relative fluorescence is inhibited.2002; Russo et al., 2001). Inhibition of cytokine synthesis and
function by means of proteasome inhibition thereby has clinical
benefit. Since both NPI-0052 and Bortezomib inhibit NF-κB,
we examined the effect of these agents on LPS-induced cyto-
kine production in human peripheral blood mononuclear cells
(PBMNCs). NPI-0052 inhibited LPS-triggered secretion of all
three cytokines at lower concentrations than Bortezomib (Fig-
ure 3C). These findings show that NPI-0052, like Bortezomib,
targets NF-κB and related cytokine secretion.
NPI-0052 blocks proteasome activity in MM cells
Our preclinical and clinical studies have already shown Borte-
zomib to be an effective therapy in MM (Hideshima and Ander-
son, 2002; Richardson et al., 2005). Our recent study showed
the composition of active proteasome in MM.1S cell line and
the proteasome targets of Bortezomib in these cells (Berkers
et al., 2005). In that study, we utilized a novel methodology
to measure proteasome activity by immunoblotting using
DansylAhx3L3VS as a probe (Berkers et al., 2005). The results
from this method correlated with those obtained using fluoro-
genic substrates and, in addition, allow for determining subunit
specificity of a given proteasome inhibitor (details provided in
the Experimental Procedures). In the present study, we exam-
ined the effects of NPI-0052 and Bortezomib on the catalytic
activities of proteasome subunits. Cells were cultured in theCANCER CELL : NOVEMBER 2005presence or absence of various concentrations of either NPI-
0052 (2 nM, low toxic dose; 7 nM, IC50; and 20 nM, highly
toxic to MM.1S cells), and compared these effects with those
triggered by Bortezomib (2 nM, low toxic dose; 5 nM, IC50; and
20 nM, highly toxic to MM.1S cells). Competition experiments
between either NPI-0052 or Bortezomib and DansylAhx3L3VS
revealed that NPI-0052 (7 nM) markedly inhibits the CT-L ac-
tivity as represented by β-5 (β-5) subunit of the protea-
some (Figure 3D). Furthermore, NPI-0052 also decreased the
DansylAhx3L3VS labeling of the β-1 (C-L activity) and β-2 (T-L
activity) in a dose-dependent manner. Slightly higher concen-
trations of Bortezomib are necessary to markedly inhibit β-5
and β-1 subunits, whereas β-2 subunits are not inhibited. To-
gether, these findings demonstrate the ability of NPI-0052 to
inhibit all three proteasome activities in MM cells and are con-
sistent with in vitro results using fluorogenic substrates shown
in Figures 1 and 2.
NPI-0052 inhibits growth and triggers
apoptosis in MM cells
We next asked whether NPI-0052-induced proteasome inhibi-
tion correlates with cytotoxicity in MM cells. Treatment for 24
hr of MM cell lines (MM.1S, RPMI-8226, OPM2, U266), includ-
ing those that are resistant to the conventional anti-MM agents
Dexamethasone (Dex) (MM.1R) and Doxorubicin (Dox-40), with409
A R T I C L EFigure 2. NPI-0052 and Bortezomib differentially affect proteasome activi-
ties in vivo
Mice (n = 5) were treated with either NPI-0052 (A, C, and E) or Bortezomib
(B, D, and F) at their respective MTD (1 mg/kg for Bortezomib and 0.15 mg/
kg for NPI-0052) for the indicated times, and blood samples were analyzed
for CT-L, C-L, and T-L proteasome activities. The data represent percent
inhibition compared to vehicle control-treated animals from two indepen-
dent experiments with similar results.NPI-0052 induces a dose-dependent significant (p < 0.005) de-
crease in viability of all cell lines (IC50 range 7–24 nM) (Figure
4A). To determine whether NPI-0052 similarly affects purified
patient cells, tumor cells from nine MM patients relapsing after
multiple prior therapies including Dex, melphalan, Bortezomib,
and Thalidomide were treated for 24 hr with NPI-0052 (10 nM)
and then analyzed for apoptosis. NPI-0052 induced significant
apoptosis in these cells, as measured by DNA fragmentation
assays (p < 0.005) (Figure 4B). Importantly, of nine patients ex-
amined four were refractory to Bortezomib therapy, and five
were resistant to Thalidomide and Dex therapies. Patients were
deemed to be refractory to Bortezomib when they had pro-
gressive disease while on Bortezomib therapy. In addition, data
from the phase II clinical studies in MM show that only 35% of
patients with relapsed/refractory MM respond to the treatment
with Bortezomib; and in this context, the 65% of patients who
were nonresponders were considered to be a Bortezomib-
resistant patient population. We next examined whether cells410from such patient populations are affected by Bortezomib
treatment in vitro and whether NPI-0052 exerts a cytotoxic ef-
fect in these cells. CD138-positive cells from seven MM pa-
tients were treated with Bortezomib (10 nM) and NPI-0052 (10
nM) in vitro and then analyzed for viability (Figure 4C). Results
demonstrate a varying sensitivity to Bortezomib in vitro, with a
15%–50% decrease in viability; however, all patient cells were
significantly more sensitive to NPI-0052 (IC50 % 10 nM in 6 of
7 patients) (Figure 4C).
The finding that cells from Bortezomib-refractory patients are
sensitive to the treatment with Bortezomib in vitro suggests
that extracellular factors, such as the BM microenvironment,
play a role in conferring drug resistance in vivo. Absence of
the BM milieu under the ex vivo culture conditions may restore
sensitivity of MM cells to Bortezomib; however, the activation
of intrinsic cellular drug mechanisms cannot be excluded. Ad-
ditionally, as noted above, NPI-0052 and Bortezomib differenti-
ally affect proteasome activities, which may explain their vari-
able in vitro cytotoxicity. Furthermore, it is unclear at present
whether alteration in any proteasome subunit confers Bortezo-
mib resistance versus sensitivity. Our data obtained from viabil-
ity studies suggest that NPI-0052 is a more potent inducer of
MM cell apoptosis than Bortezomib in tumor cells obtained
from Bortezomib-refractory MM patients.
NPI-0052 does not affect viability of patient MM-derived
bone marrow stromal cells
Interaction of MM cells with bone marrow stromal cells
(BMSCs) induces cytokine secretion, which mediates paracrine
growth of MM cells, as well as protects against drug-induced
apoptosis (Hideshima and Anderson, 2002). We examined
whether NPI-0052 affects viability of BMSCs. Treatment of
BMSCs (patients 1–5) for 24 hr with NPI-0052 (20 nM) does not
induce apoptosis in these cells, whereas NPI-0052 triggered a
significant (10- to 12-fold) increase in apoptosis of purified pa-
tient MM cells (Figure 4D). Importantly, NPI-0052 significantly
decreased the secretion of IL-6 triggered by adhesion of MM
cells to BMSCs (IC50, 80–100 nM; p < 0.05), as is observed
using Bortezomib (Anderson, 2004). Together, these results
suggest that NPI-0052 does not directly affect BMSC viability,
but blocks the secretion of BMSC-derived MM cell growth fac-
tor IL-6 within the BM milieu.
NPI-0052 overcomes recombinant human interleukin-6-
and recombinant human insulin-like growth factor-I-
mediated antiapoptotic effects
Both IL-6 and IGF-I trigger growth and protect against chemo-
therapy-induced apoptosis in MM cells (Chauhan and Ander-
son, 2003; Xu et al., 1997). We therefore next examined
whether NPI-0052 overcomes this protective effect of IL-6 or
IGF-I. Neither recombinant human interleukin-6 (rhIL-6) nor re-
combinant human insulin-like growth factor-I (rhIGF-I) blocks
NPI-0052-triggered cytotoxicity in MM.1S cells (Figure 4E). As
in our prior studies (Chauhan and Anderson, 2003; Mitsiades
et al., 2002a), both rhIL-6 and rhIGF-I block Dex-induced de-
creases in MM.1S cell viability. High serum levels of IL-6 or
IGF-I contribute to clinical chemoresistance and treatment fail-
ure (Hideshima and Anderson, 2002), and our data therefore
suggest a remarkable ability of NPI-0052 to induce MM cell
apoptosis even in the presence of IL-6 or IGF-I.CANCER CELL : NOVEMBER 2005
A R T I C L EFigure 3. Orally bioactive NPI-0052 inhibits cytokine secretion, NF-κB, and proteasome activities
A: NPI-0052 is orally bioactive. Mice (n = 5) were administered NPI-0052 i.v. or orally, and CT-L activity of the 20S proteasome in WBC lysates was determined.
Relative fluorescence units (RFU) were normalized for protein concentrations of the cell lysates. The 20S proteasome activity of the individual mice is
shown, with the horizontal bar representing the average activity. Baseline represents 20S proteasome activity observed in WBC lysates prepared from
untreated mice.
B and C: NPI-0052 inhibits NF-κB and the cytokine secretion. Effect of NPI-0052 and Bortezomib on NF-κB activity in NF-κB/Luc HEK-293 cells and LPS-triggered
cytokine secretion in PBMNCs.
D: Competition experiment between NPI-0052 or Bortezomib and DansylAhx3L3VS (upper panel). The three distinct catalytic activities of proteasome are
represented by β-1 for caspase-like, β-2 for Trypsin-like, and activity β-5 for chymotrypsin-like activities. The β-2i and β-5i are the interferon-inducible subunits
to form immunoproteasomes with altered catalytic specificity that help production of antigenic peptides. Filters were reprobed with anti-α-actin Ab to
show equal protein loading. Blots shown are representative of two independent experiments.NPI-0052 blocks vascular endothelial growth
factor-induced migration of MM cells
Vascular endothelial growth factor (VEGF) is elevated in the
MM BM microenvironment, and our studies showed that VEGF
triggers growth, migration, and angiogenesis in MM (Podar et
al., 2002). We therefore asked whether NPI-0052 affects VEGF-
triggered MM cell migration. VEGF alone markedly increases
MM.1S cell migration; conversely, NPI-0052 significantly (p <
0.05) inhibits VEGF-dependent MM cell migration (Figure 4F).
The short exposure time of MM.1S cells to NPI-0052 did not
affect survival of MM cells (viability > 95%). These findings indi-
cate that NPI-0052 may negatively regulate homing of MM
cells to the BM, as well as their egress into the peripheral
blood.
NPI-0052 inhibits human MM cell growth in vivo
and prolongs survival in a murine model
Having shown that NPI-0052 induces apoptosis in MM cells
in vitro, we next examined the in vivo efficacy of NPI-0052CANCER CELL : NOVEMBER 2005using our human plasmacytoma xenograft mouse model
(LeBlanc et al., 2002). As noted above, NPI-0052 has achieved
therapeutically effective levels of proteasome inhibition after
oral administration in mice, and we therefore administered NPI-
0052 orally. Treatment of tumor-bearing mice with NPI-0052,
but not vehicle alone, significantly (p < 0.001) inhibits MM tu-
mor growth and prolongs survival (p < 0.001) of these mice
(Figures 5A–5C). The concentrations of NPI-0052 administered
were well tolerated by mice, without significant weight loss (see
Figure S1 in the Supplemental Data available with this article
online). Moreover, no neurological behavioral changes were ob-
served even after 12 weeks of NPI-0052 treatment. Analysis at
day 300 showed no recurrence of tumor in 57% of the NPI-
0052-treated mice (Figure 5C). In addition, histologic analysis
performed on the inoculation sites confirmed the disappear-
ance of plasma cells in the NPI-0052- versus vehicle-treated
mice (Figure 5D, left and right panels, respectively). These data
demonstrate the potent antitumor activity of NPI-0052 in vivo.
Importantly, these findings also show that NPI-0052 is orally411
A R T I C L EFigure 4. NPI-0052 induces apoptosis in human MM cells
A: MTT assays were performed after incubation of MM.1S (black squares), MM.1R (white boxes), RPMI-8226 (black circles), Dox-40 (black squares), OPM2
(white circles), and U266 (white diamonds) human MM cells with indicated concentrations of NPI-0052 for 24 hr. Data represent mean ± SD (error bars)
from three independent experiments (p < 0.005 for all cell lines).
B: Purified MM cells from patients were treated for 24 hr with NPI-0052 (10 nM) and then analyzed for apoptosis. Data represent mean ± SD (error bars) of
triplicate samples (p < 0.005 for all patient MM cells).
C: Tumor cells from MM patients refractory (patients 1, 2, 4, and 7) or sensitive (patients 3, 5, and 6) to Bortezomib therapy were treated with either NPI-
0052 (10 nM) or Bortezomib (10 nM) for 24 hr and then analyzed for viability. Shown is mean ± SD (error bars) of duplicate samples (p < 0.004 for all samples).
D: Effect of NPI-0052 on bone marrow (BM) microenvironment. Patient MM-derived BM stromal cells (BMSCs) were treated for 24 hr with NPI-0052 (20 nM)
and then analyzed for apoptosis. Purified MM cells from two of these five MM patients were similarly examined. Data represent mean ± SD (error bars)
from triplicate samples (p < 0.005).
E: MM.1S cells were treated for 24 hr with the indicated concentrations of NPI-0052 or Dex, in the presence or absence of rhIL-6 or rhIGF-I, and then
analyzed for viability. Shown is mean ± SD (error bars) of three independent experiments (p < 0.04 for all samples).
F: MM.1S MM cells were treated with indicated concentrations of NPI-0052 for 4 hr (viability > 95%), washed, and then treated for 24 hr with rhVEGF
(10 ng/ml), followed by analysis in a transwell migration assay. Data represent mean ± SD (error bars) of two independent experiments (p < 0.005 for
all samples).bioactive, which together with the in vivo proteasome inhibition
studies (Figures 2 and 3A), provides the preclinical framework
for its evaluation as an oral agent in phase I trials in MM.
Comparative analysis of in vivo antitumor activity
of NPI-0052 and Bortezomib
Our prior study using the human plasmacytoma xenograft
mouse model established the MTD of Bortezomib at 1 mg/kg
(i.v.) (LeBlanc et al., 2002). Using the same animal model, we
obtained the MTD of NPI-0052 at 0.15 mg/kg (i.v.) (data not
shown). For the comparative study, we therefore selected the
MTD of each agent. Mice were treated with NPI-0052 (0.15 mg/
kg i.v.) or Bortezomib (1.0 mg/kg i.v.) twice weekly, the optimal
dose and schedule reported for Bortezomib (LeBlanc et al.,4122002). Both agents significantly reduced the tumor progression
(p < 0.01) and prolonged survival (p = 0.0137) (Figures 5E
and 5F).
Mechanisms mediating anti-MM activity of NPI-0052
We first studied mitochondria, given their critical role in apo-
ptosis (Bossy-Wetzel and Green, 1999). NPI-0052 decreases
Ψm, evidenced by an increased number of CMXRos-negative
cells (p < 0.005) (Figure 6A), and also triggers O2− production
in MM.1S cells (Figure 6B). Moreover, NPI-0052 decreases
mitochondrial cyto-c and Smac (Figure 6C, upper and middle
left panels), coupled with a concurrent accumulation of these
proteins in the cytosol (Figure 6C, upper and middle right pan-
els). As in previous studies (Chauhan et al., 2001; Chauhan etCANCER CELL : NOVEMBER 2005
A R T I C L EFigure 5. NPI-0052 inhibits human plasmacytoma growth and increases survival in immune-deficient BNX mice
A: Photographs. The mouse on the upper panel received oral doses of vehicle alone, whereas the mouse in the lower panel received oral NPI-0052 (0.25
mg/kg twice weekly). Left panels are enlargements of subcutaneous plasmacytomas growing on the flanks of the mice.
B: Kinetics of myeloma xenograft growth. Mice (n = 7) received NPI-0052 orally at the indicated doses twice weekly. A significant delay in tumor growth in
NPI-0052-treated mice was noted compared to vehicle-treated control mice, as early as day 15 (p < 0.001). No significant differences between the NPI-
0052 treatment groups were observed.
C: Kaplan-Meier plots showing survival for mice treated with NPI-0052 at the indicated concentrations. NPI-0052-treated mice show significantly increased
survival (p < 0.001) compared to the untreated group. The mean overall survival (OS) was 58 days (95% confidence interval [CI], 44–73 days) in the control
cohort versus 196 days (95% CI, 130–262 days) and 182 days (95% CI, 107–258 days) in groups treated with 0.25 and 0.5 mg/kg NPI-0052, respectively. A
statistically significant prolongation in mean OS compared with control mice was observed in animals treated with 0.25 mg/k (p = 0.0019) and 0.5 mg/kg
(p = 0.0074).
D: Histology. Tissue sections of inoculation sites from a treated and a control mouse were examined under an Olympus BX60 inverted microscope (Olympus,
Lake Success, NY) equipped with Hoffman objective lenses (×10/×20/×40; Diagnostic Instruments, Sterling Heights, MI) connected to a SPOT One Digital
Camera (Diagnostic Instruments). Images were then processed using Adobe Photoshop software (Adobe, San Jose, CA). Left panel shows extensive
subcutaneous infiltration with plasma cells replacing the subcutaneous connective tissue and fat. Right panel shows disappearance of the subcutaneous
tumor in a mouse treated with NPI-0052. The thin arrow indicates the cutaneous layer, and the thick arrow shows subcutaneous tissue. Scale bar, 10
M (micrometers).
E: Comparative analysis of NPI-0052- and Bortezomib-triggered effects on myeloma xenograft growth. Treatment with either 0.15 mg/kg NPI-0052 or 1.0
mg/kg Bortezomib (n = 7 per group) significantly delayed tumor growth versus control group (p < 0.01).
F: Treatment with either 0.15 mg/kg NPI-0052 or 1.0 mg/kg Bortezomib significantly increases survival (p < 0.0137) compared to treatment with either vehicle
alone. A statistically significant prolongation in mean OS compared with control mice was observed in animals treated with Bortezomib (p = 0.003) and
NPI-0052 (p = 0.01).al., 1997), the release of cyto-c and Smac from mitochondria
to cytosol correlates with caspase-9 activation (Figure 6D). Be-
sides caspase-9, NPI-0052 also activates caspase-8 (Figure
6E), followed by activation of downstream effector caspase-3
(Miller, 1999), and proteolytic cleavage of PARP (Figure 6F,
lower and upper panels). Together, these findings show that
NPI-0052, like Bortezomib, triggers both mitochondria-depen-
dent and -independent signaling pathways.
Differential requirement of caspases and mitochondrial
signaling during NPI-0052- and Bortezomib-induced
MM cell apoptosis
We next defined the requirement for caspase-8 versus cas-
pase-9 during NPI-0052- and Bortezomib-induced apoptosis.CANCER CELL : NOVEMBER 2005Incubation of MM.1S cells with pan-caspase inhibitor (Z-VAD-
FMK) markedly abrogates both NPI-0052- and Bortezomib-
induced apoptosis (Figure 7A). Inhibition of caspase-8 (IETD-
FMK) led to a significant decrease in NPI-0052-triggered cell
death, and inhibition of caspase-9 (LEHD-FMK) only moderately
blocked NPI-0052-triggered decreased viability in MM.1S cells
(p < 0.005; n = 4), whereas Bortezomib-induced decreases in
viability are equally blocked by either caspase-8 or caspase-9
inhibitor (p < 0.005; n = 4) (Figure 7A). These biochemical data
were confirmed by genetic studies using dominant-negative (DN)
strategies. Treatment of DN-caspase-8-transfected MM cells with
NPI-0052 (IC50, 7 nM) markedly increases survival of these cells,
compared to the cells transfected with DN-caspase-9 (Figure 7B).
In contrast, treatment of either DN-caspase-8 or DN-caspase-9-413
A R T I C L EFigure 6. NPI-0052-induced apoptotic signal transduction
A: MM.1S cells were treated with NPI-0052 (7 nM) for the indicated times and then analyzed by flow cytometry for alterations in mitochondrial membrane
potential (Ψm). Data are mean ± SD (error bars) of two independent experiments (p < 0.005).
B: MM.1S cells were treated with NPI-0052 for the indicated times, stained with dihydroethidium, and analyzed by flow cytometry. Shown is mean ± SD
(error bars) of two independent experiments (p < 0.005).
C: Immunoblot analysis of NPI-0052-treated MM.1S cells showing alterations of cyto-c and Smac levels (upper and middle panels). Blots were reprobed
with anti-Hsp60 and anti-tubulin Abs (lower left and lower right panels).
D–F: MM.1S cells were treated for 24 hr with NPI-0052 (7 nM) and harvested; cytosolic proteins were subjected to immunoblot analysis using anti-cas-
pase-9, -caspase-8, and -caspase-3 and PARP Abs. “FL” indicates full length; “CF” denotes cleaved fragment. Blots shown are representative of three
independent experiments.tranfected MM.1S cells with Bortezomib (IC50, 5 nM) increased
the survival to a similar extent. The functional specificity of DN-
caspase-8 and DN-caspase-9 was confirmed by treatment of
MM.1S cells with known inducers of caspase-9 (Dex) and cas-
pase-8 in these cells (anti-Fas MoAb) (Chauhan et al., 1997)
(Figure 7C). These data suggest that (1) NPI-0052-induced MM
cell apoptosis is predominantly mediated by caspase-8; and
(2) Bortezomib-induced apoptosis requires both caspase-8
and caspase-9 activation.
We next determined whether inhibition of an upstream sig-
naling pathway that leads to caspase-8 activation affects the
response to NPI-0052 or Bortezomib. The Fas-associated
death domain (FADD) protein is an essential part of the death-
inducing signaling complexes (DISCs) that assemble upon en-
gagement of TNF receptor family members, such as Fas
(Strasser et al., 2000), resulting in proteolytic processing and
autoactivation of pro-caspase-8 (Strasser et al., 2000). Since
both NPI-0052 and Bortezomib trigger caspase-8 activation,
we examined the role of FADD during this event in MM cells
using DN-FADD. Blockade of FADD with DN-FADD significantly414attenuated NPI-0052-induced cytotoxicity compared to the
empty vector-transfected MM.1S cells (42% ± 2.0% viable
cells in vector-transfected cells versus 76% ± 5.1% viable cells
in DN-FADD-transfected cells; p < 0.05) (Figure 7D). DN-FADD
decreases NPI-0052-induced caspase-8 activation; however,
minimal caspase-8 activation is still noted (data not shown),
which may be due to upstream activators of caspase-8 other
than FADD. Importantly, treatment of DN-FADD-transfected
MM.1S cells with Bortezomib results in only a 16% increase in
survival compared to vector-transfected cells (39% ± 2.4% via-
ble cells in vector-transfected cells versus 55% ± 4.1% viable
cells in DN-FADD-transfected cells; p < 0.05) (Figure 7D). These
data, coupled with caspase-8 or caspase-9 inhibition studies,
suggest that NPI-0052 relies more on FADD-caspase-8 signal-
ing axis than does Bortezomib, further confirming differential
mechanism of action of NPI-0052 versus Bortezomib in MM
cells.
To further address this issue, we examined the alterations in
Bax, a proapoptotic protein that translocates from cytosol to
mitochondria during apoptosis, inhibits Bcl-2, and facilitatesCANCER CELL : NOVEMBER 2005
A R T I C L EFigure 7. Role of caspase-8 versus caspase-9 during NPI-0052- and Bortezomib-induced apoptosis
A: MM.1S cells were treated for 24 hr with NPI-0052 (10 nM) or Bortezomib (10 nM) in the presence or absence of pan-caspase, caspase-8, or caspase-9
inhibitors and then assessed for viability. Shown is mean ± SD (error bars) of four independent experiments (p < 0.004).
B: MM.1S cells transfected with vector alone, DN-caspase-8 (Cas.8), or DN-Cas.9 were treated for 48 hr with NPI-0052 (7 nM) or Bortezomib (5 nM) and
then analyzed for cell viability.
C: Control for functional specificity of DN-Cas.9 and DN-Cas.8. MM.1S cells were transiently transfected with vector alone, DN-Cas.9, or DN-Cas.8 and
treated for 24 hr with either Dexamethasone (Dex; 5 M) (upper panel) or anti-Fas MoAb (lower panels). Cytosolic extracts were analyzed by immunoblot-
ting with anti-Cas.9, anti-Cleaved Cas.8, or anti-tubulin Abs. Blots shown are representative of two independent experiments.
D: Vector- or DN-FADD-transfected MM.1S cells were treated for 48 hr with NPI-0052 (7 nM) or Bortezomib (5 nM) and then analyzed for cell viability.
E: Mitochondrial protein extracts from NPI-0052- or Bortezomib-treated MM.1S cells were subjected to immunoblot analysis with anti-Bax (upper panel) or
anti-Hsp60 (lower panel) Abs.
F: The MEFs Bax and Bak (wild-type or double knockouts) were treated with NPI-0052 or Bortezomib and analyzed for viability. Data represent mean ± SD
(error bars) of three independent experiments (p < 0.05).release of cyto-c and activation of caspase-9 (Guo et al., 2003;
Wei et al., 2001). NPI-0052 induces little, if any, increase in Bax
levels in mitochondria, whereas Bortezomib triggers a signifi-
cant accumulation of Bax in mitochondria (Figure 7E, upper
panel). Previous studies showed that oligomerization of Bax
with another proapoptotic Bcl-2 family member, Bak, facilitates
release of cyto-c from mitochondria to the cytosol, resulting in
caspase-9 activation and cell death (Wei et al., 2001). Reports
in Bax/Bak knockout mice showed that these proteins are re-
quired for mitochondria-mediated cell death (Wei et al., 2001).
We therefore examined the effects of Bortezomib and NPI-
0052 on DKO mouse embryonic fibroblasts lacking both Bax
and Bak. Deletion of Bax and Bak markedly inhibits Borte-
zomib- but not NPI-0052-mediated cytotoxicity (Figure 7F).
These findings indicate that, in contrast to NPI-0052-, Bortezo-
mib-mediated cell death requires mitochondrial apoptotic sig-
naling via Bax and Bak.CANCER CELL : NOVEMBER 2005A recent study showed that Bax and Bak can also localize in
the endoplasmic reticulum (ER) and that ER stress can trigger
caspase-12 activation (Zong et al., 2003). Bortezomib induces
ER stress (Mitsiades et al., 2002b) and activates ER-resident
caspase-12 in MM cells (Landowski et al., 2005). Another study
showed that caspase-12 and caspase-4 are not required for
caspase-dependent ER stress-induced apoptosis (Obeng and
Boise, 2005). Whether caspase-12 or caspase-4 has an obli-
gate role during NPI-0052-triggered cell death remains to be
examined.
Differential effects of NPI-0052 and Bortezomib
on Bcl-2-overexpressing MM cells
As noted above, during apoptosis Bax neutralizes the anti-
apoptotic function of Bcl-2, thereby facilitating the cyto-c re-
lease and caspase-9 activation (Rathmell and Thompson,
2002; Willis et al., 2003). Bcl-2 also confers drug resistance in415
A R T I C L Ecancer cells, including MM (Hideshima and Anderson, 2002),
and provides partial protection against Bortezomib-induced
killing (Mitsiades et al., 2002b). We therefore next asked
whether ectopic expression of Bcl-2 in MM.1S cells affects the
ability of NPI-0052 or Bortezomib to trigger cytotoxicity and
postmitochondrial apoptotic signaling in MM cells. Overex-
pression of Bcl-2 promotes a modest increase in viability of
cells treated with both agents: for NPI-0052, 50% ± 2.6% via-
bility in Bcl-2-transfected cells versus 39% ± 1.5% viability in
vector-transfected cells (p < 0.05); and for Bortezomib, 61% ±
2.9% viability in Bcl-2-transfected cells versus 40% ± 2.1%
viability in vector-transfected cells (p < 0.05) (Figure 8A). Impor-
tantly, the increased survival of Bcl-2 transfectants in response
to Bortezomib was greater (21%) than that in response to NPI-
0052 (11%) (p < 0.04; n = 3) (Figure 8A). Moreover, Bortezomib
triggers significant caspase-9 cleavage in control vector-trans-
fected cells, which is markedly attenuated (3-fold decrease byFigure 8. NPI-0052 decreases survival in Bcl-2-overexpressing MM.1S cells
A: Left panel: empty vector- or Bcl-2-transfected MM.1S cells were treated for 48 hr with NPI-0052 (10 nM) or Bortezomib (10 nM) and then analyzed for
viability. Results are mean ± SD (error bars) of three independent experiments. Right panel: Bcl-2 protein levels in MM.1S cells transfected with Bcl-2 or
empty (neo) vector.
B: Vector- or Bcl-2-transfected MM.1S cells were treated for 48 hr with NPI-0052 (7 nM) or Bortezomib (5 nM), and cytosolic extracts were analyzed by
immunoblotting with anti-Cleaved Cas.9 or anti-tubulin Abs. Blots shown are representative of two independent experiments.
C: Differential cytotoxicity of NPI-0052 and Bortezomib against lymphocytes from healthy donors. Normal lymphocytes from five healthy donors were
treated with indicated concentrations of NPI-0052 or Bortezomib and then analyzed for viability. Data are mean ± SD (error bars) of three independent
experiments (p = 0.27 from Jonchkeere-Tepstra test for trend).
D: NPI-0052 and Bortezomib trigger synergistic anti-MM activity. Low doses of NPI-0052 and Bortezomib trigger synergistic anti-MM activity in MM cells.
MM.1S and MM.1R cells were treated for 24 hr with indicated concentrations of NPI-0052, Bortezomib, or NPI-0052 + Bortezomib and then assessed for
viability. Shown is mean ± SD (error bars) of three independent experiments (p < 0.005). Combination index (CI) of <1 indicates synergy.416densitometry) in Bcl-2-transfected cells; in contrast, NPI-0052-
induced caspase-9 cleavage is minimally affected by Bcl-2
overexpression (Figure 8B). These findings, together with the
viability results, suggest that Bcl-2 provides more protection
against Bortezomib than NPI-0052.
NPI-0052 and Bortezomib have differential effects
on normal lymphocytes
Our data demonstrate that NPI-0052 and Bortezomib protea-
some inhibitors have differential mechanisms of action. It is
also possible, due to differences in their chemical structure,
specificity, or signaling mechanisms, that these agents may
have different cytotoxic activities against normal cells. To ad-
dress this issue, we compared the effects of NPI-0052 and
Bortezomib on normal lymphocytes. NPI-0052 does not signifi-
cantly decrease viability of normal lymphocytes (p = 0.27 from
Jonckheere-Terpstra [J-T] trend test) even at the increasedCANCER CELL : NOVEMBER 2005
A R T I C L Edoses (20 nM) (Figure 8C). Higher concentrations of NPI-0052
at 50 and 100 nM decrease the viability of lymphocytes by
25% and 50%, respectively. These data suggest that normal
cells are not completely refractory to NPI-0052. In contrast,
Bortezomib significantly decreases the survival of lymphocytes
even at the low concentrations of 6–10 nM (Figure 8C), as is
observed in clinical studies (Adams, 2002; Richardson, 2004).
Importantly, the IC50 for patient MM cells of NPI-0052 or Bor-
tezomib is at concentrations that do not affect viability of nor-
mal lymphocytes; however, dose escalation of each agent
suggests a larger therapeutic index for NPI-0052 than for Bor-
tezomib. Moreover, a 50% decrease in viability of normal CCD-
27sk fibroblasts is observed at 317 ± 17 nM NPI-0052 versus
15 ± 3 nM Bortezomib (p < 0.05), suggesting that NPI-0052
has significantly reduced cytotoxicity against normal cells
than Bortezomib.
We further examined whether NPI-0052 or Bortezomib alters
proteasome activity in normal lymphocytes and skin fibro-
blasts. Both NPI-0052 and Bortezomib significantly inhibit pro-
teasome activity in these cells: 20 nM NPI-0052 or Bortezomib
triggers 99% or 59 ± 11% inhibition of CT-L proteasome activ-
ity, respectively (data not shown). Thus, although 20 nM NPI-
0052 does not trigger significant cytotoxicity in normal lym-
phocytes, it reduces CT-L proteasome activity in these cells.
Similarly, treatment of normal CCD-27sk fibroblasts at the IC50
for NPI-0052 (317 nM) or Bortezomib (15 nM) also inhibits pro-
teasome activity (data not shown). Bortezomib inhibits 20S
proteasome activity in murine WBCs at 1 hr post-i.v. injections
(Adams et al., 1999). Furthermore, these data are consistent
with the clinical observation showing a similar degree of pro-
teasome inhibition in blood from responders versus nonre-
sponders to Bortezomib therapy (Adams, 2002; Richardson,
2004). Nonetheless, these findings demonstrate a selective
anti-MM activity of NPI-0052.
Combined Bortezomib and NPI-0052 treatment triggers
synergistic apoptosis in MM cells
The proteasome inhibitors Bortezomib and NPI-0052 are dis-
tinct, providing the rationale for combining these agents to en-
hance anti-MM activity. MM.1S or MM.1R MM cells were
treated with both NPI-0052 and Bortezomib simultaneously
across a range of concentrations and analyzed for viability. Re-
sults demonstrate that NPI-0052 and Bortezomib induce syn-
ergistic cytotoxicity (Figure 8D; shown are the representative
results from minimally toxic and maximally synergistic concen-
trations of each agent). Isobologram analysis confirmed syner-
gistic anti-MM activity of Bortezomib with NPI-0052 (combina-
tion index < 1.0). Importantly, combining low doses of these
two agents does not significantly affect the viability of normal
lymphocytes (Figure S2). While the definitive demonstration of
decreased toxicity of combination therapy awaits results of
careful clinical trials, the synergy observed in vitro may allow
for use of lower doses and decreased toxicity.
The mechanisms mediating the enhanced cytotoxicity of the
combination may simply reflect higher levels of proteasome in-
hibition with the two-drug regimen, and our ongoing studies
are examining this issue in MM animal models using various
parameters to determine the proteasome activity profiles of
combination therapy, such as drug route, dose, and sequence
of administration. Nonetheless, our present study shows that
these two agents trigger differential apoptotic signaling path-CANCER CELL : NOVEMBER 2005ways, which may account for the enhanced cytotoxicity upon
combined treatment. Activation of different apoptotic signaling
cascades provides the basis for combining two drugs to en-
hance cell death (Chauhan and Anderson, 2003). Another
recent study also showed that Bortezomib sensitizes to TRAIL-
induced apoptosis in genitourinary cancer cells via p21 accu-
mulation and enhanced caspase-8 activation (Lashinger et al.,
2005). Combination therapy with Bortezomib and NPI-0052
therefore may (1) allow use of subtoxic concentrations of each
agent and (2) permit escalating synergistic doses of these
agents to increase the apoptotic threshold, thereby enhancing
anti-MM activity.
Collectively, our study shows the following: (1) a novel pro-
teasome inhibitor, NPI-0052, inhibits proteasome activity both
in vitro and in vivo at pharmacologically achievable concentra-
tions and exhibits a different proteasome inhibition profile than
Bortezomib; (2) NPI-0052 is a more potent inhibitor of NF-κB
and related cytokine secretion than Bortezomib; (3) NPI-0052
induces apoptosis in MM cells resistant to conventional and
Bortezomib therapies, without affecting normal lymphocyte vi-
ability; (4) NPI-0052 does not affect viability of BMSCs; (5) NPI-
0052 induces MM cell apoptosis even in the presence of MM
growth factors, such as IL-6 or IGF-1; (6) NPI-0052 blocks
VEGF-induced migration of MM cells, confirming its antiangio-
genic activity; (7) NPI-0052 overcomes drug resistance con-
ferred by the antiapoptotic protein Bcl-2; (8) NPI-0052-induced
apoptosis in MM cells is associated with loss of Ψm, increase
in O2− production, release of cyto-c/Smac, and activation of
caspase-8, caspase-9, and caspase-3; (9) both biochemical
and genetic evidence indicate that NPI-0052, in contrast to
Bortezomib, relies more on the FADD-caspase-8-mediated cell
death signaling pathway; (10) combinations of low doses of
NPI-0052 and Bortezomib trigger synergistic anti-MM activity;
(11) NPI-0052 inhibits MM tumor growth in vivo, as well as pro-
longs, survival without reoccurrence of tumor in 57% mice; and
finally, (12) NPI-0052 is orally bioactive. Together, these find-
ings provide the framework for clinical trials of NPI-0052, either
alone or in combination with Bortezomib, to enhance clinical
efficacy, reduce toxicity, and overcome drug resistance in pa-
tients with relapsed/refractory MM.
Experimental procedures
In vitro and in vivo proteasome activity assays
Proteasome activity assays were performed using purified human erythro-
cyte-derived 20S proteasomes, as previously described (Lightcap et al.,
2000). In vivo comparative analysis of proteasome activities were performed
as follows. Single i.v. administration of NPI-0052: NPI-0052 was dissolved
in 100% DMSO and serially diluted with 5% Solutol (Solutol HS 15; polyeth-
ylene glycol 660 12-hydroxystearate; BASF, Shreveport, LA), yielding a final
concentration of 2% DMSO. The vehicle control consisted of 2% DMSO
and 98% (5% Solutol). Male Swiss-Webster mice (n = 5) were treated with
a single dose of NPI-0052 (0.15 mg/kg) or Bortezomib (1 mg/kg); blood
samples were collected at 90 min, 24 hr, 48 hr, 72 hr, or 168 hr; and whole
blood cells were then analyzed for proteasome activity. Further details are
found in the Supplemental Data.
Assaying proteasome activity by immunoblotting
The method has been described previously (Berkers et al., 2005). Briefly,
the principle is as follows: DansylAhx3L3VS is a proteasome inhibitor that
covalently modifies all active proteasome subunits with comparable affin-
ity (Bogyo et al., 1998; Kessler et al., 2001). This proteasome probe is
equipped with a dansyl-sulfonamidohexanoyl hapten and can be visualized
by immunoblotting using polyclonal antibodies against the dansyl moiety.417
A R T I C L EIn the assay, sites that are not targeted by NPI-0052 or Bortezomib are
labeled by DansylAhx3L3VS and visualized on Western blot, while sites that
are targeted by NPI-0052 or Bortezomib cannot be seen. Equal amounts of
protein (60 g) from Bortezomib- or NPI-0052-treated MM.1S cells were
incubated with 0.8 M DansylAhx3L3VS at 37°C and subjected to immu-
noblotting using an anti-dansyl-sulfonamidohexanoyl polyclonal Ab (1:500,
rabbit; Molecular Probes, Carslbad, CA).
Human plasmacytoma xenograft models
All experiments involving animals were approved by an institutional Animal
Care and Use Committee. The xenograft tumor formation was performed
as previously described (LeBlanc et al., 2002). Briefly, mice (n = 7/group)
were inoculated subcutaneously in the flank with 3 × 107 MM.1S MM cells
in 100 l of RPMI-1640 media. NPI-0052 treatment was started after the
development of measurable tumor (120–180 mm3 size). NPI-0052 (0.25 mg/
kg or 0.5 mg/kg) was given orally twice a week. For comparative studies,
mice were treated by the i.v. route with NPI-0052 (0.15 mg/kg) or Bortezo-
mib (1 mg/kg) twice a week. Tumor measurements were taken on alternate
days with a caliper, and tumor volume was calculated according to the
equation 1/2 (length [mm] × width [mm])2. Animals were sacrificed if the
tumor was R2 cm or exhibited visible signs of necrosis.
Expression vectors and transfections
MM.1S cells were transiently transfected using Cell line Nucleofecto kit V,
according to the manufacturer’s instructions (Amaxa Biosystems, Ger-
many), with vector alone, DN-caspase-8, DN-caspase-9, or DN-FADD and
cotransfected with vector containing green fluorescence protein (GFP)
alone. Following transfections, GFP-positive cells were selected by flow
cytometry, treated with NPI-0052 or Bortezomib, and analyzed for viability.
Statistical analysis
Nonparametric tests and mixed models were used to analyze the data. This
includes the Wilcoxon signed rank test to compare proliferation in untreated
and treated patient cells and the J-T trend test for measuring the viability
of lymphocytes and cell lines resistant to conventional therapy. Wilcoxon
rank-sum test was used for measuring change in the tumor volume, the
Kaplan-Meier method was used for survival analysis, and log-rank analysis
was used for statistical significance.
Isobologram analysis
Isobologram analysis was performed using the CalcuSyn software program
(Biosoft, Ferguson, MO and Cambridge, UK), and a combination index (CI)
of <1.0 indicates synergism (Chou and Talalay, 1984).
Supplemental data
Information on MM cell lines and culture medium, reagents, purification of
CD138-positive MM patient BM samples, PBMNC preparation from normal
healthy donors, cytotoxicity and apoptosis assays, transwell migration as-
says, protein extraction, mitochondrial assays, immunoblotting, and anti-
bodies can be found in the Supplemental Data. The Supplemental Data
include two supplemental figures as well as the Supplemental Experimen-
tal Procedures and can be found with this article online at http://www.
cancercell.org/cgi/content/full/8/5/407/DC1/.
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